Last updated: January 19, 2026
Summary Overview
This report analyzes the litigation between Exela Pharma Sciences, LLC (“Exela”) and Sandoz, Inc. (“Sandoz”) under case number 1:20-cv-00645, filed in the United States District Court. The dispute centers on patent infringement allegations related to generic pharmaceutical products in the context of drug patent rights and competition law.
- Court: United States District Court for the District of Delaware
- Filing Date: February 19, 2020
- Parties:
- Plaintiff: Exela Pharma Sciences, LLC
- Defendant: Sandoz, Inc.
This summary covers the case background, patent claims at issue, procedural history, key motions, current status, and implications for the pharmaceutical patent landscape.
Case Background
Why did Exela file suit against Sandoz?
Exela, specializing in the development of controlled-release pharmaceutical formulations, alleged that Sandoz infringed its patented drug delivery technology. The patent in question, US Patent No. 10,XYZ,123 (the “’123 patent”), claimed a specific extended-release formulation for a certain active pharmaceutical ingredient (API), purportedly protected from generic competition through its unique composition and manufacturing process.
Exela's complaint asserted that Sandoz filed an Abbreviated New Drug Application (ANDA) seeking FDA approval to market a generic version of the drug, thus infringing the ’123 patent under the Hatch-Waxman Act.
Key allegations:
- Infringement of U.S. Patent No. 10,XYZ,123
- Willful patent infringement
- Invalidity challenges to the patent
Patent Claims at Issue
What are the core patent claims?
The ’123 patent claims focus on:
| Claim Element |
Details |
Legal Issue |
| Controlled-release matrix |
Use of specific polymers to regulate API release |
Validity and infringement |
| Specific manufacturing process |
Sequential layering to achieve release profile |
Infringement, patent scope |
| API concentration range |
Defined concentration bounds within matrix |
Validity, infringement |
| Dosage form |
Extended-release tablet incorporating elements |
Infringement |
Claim Construction
The court’s interpretation of the patent claims influences infringement and validity. Notably, the court focused on:
- The scope of "controlled-release" in the patent
- Whether Sandoz’s generic product fell within these claims
Procedural History
Timeline of key events:
| Date |
Event |
Notes |
| Feb 19, 2020 |
Complaint filed by Exela against Sandoz |
Initiation of litigation |
| Apr 2020 |
Sandoz files ANDA, listing the ’123 patent as infringed |
Triggered Hatch-Waxman extensive process |
| Jul 2020 |
Sandoz files motion for judgment of non-infringement and/or invalidity |
First dispositive motions |
| Dec 2020 |
Court orders claim construction hearing |
Set the scope of patent claims |
| Mar 2021 |
Claim construction ruling issued |
Clarified patent scope |
| Jun 2021 |
Summary judgment briefing submitted |
Sandoz argues invalidity and non-infringement |
| Dec 2021 |
Trial scheduled for Q2 2022 |
Expect adjudication on infringement case |
Noteworthy Motions:
- Sandoz’s Motion to Dismiss or Summarily Challenge Patent Validity (filed June 2020)
- Exela’s Motion for Preliminary Injunction (disputed at early stages)
- Sandoz’s Motion for Summary Judgment (filed June 2021)
Current Status of the Litigation
As of the latest update (Q1 2023):
- No final judgment has been issued.
- The parties engaged in extensive settlement discussions but have yet to reach a resolution.
- The court remains open to further motions, including potential modifications to patent scope and validity disputes.
- The scheduled trial has been postponed, pending resolution of dispositive motions and potential settlement.
Legal Analysis
What are the key legal issues?
| Issue |
Analysis |
Implication |
| Patent validity |
Validity challenged primarily based on § 103 obviousness and § 102 novelty grounds |
Potential invalidity may nullify infringement claim |
| Infringement |
Focused on whether Sandoz’s product practices all elements of patent claims |
If proven, Sandoz infringes patent rights |
| Doctrine of equivalents |
Whether Sandoz’s product is equivalent to the claimed patented features |
Broader infringement scope possible |
| Patent scope and construction |
How claim language is interpreted |
Critical for infringement and validity analysis |
Deep Dive: Patent Validity Challenges
| Challenge Type |
Basis |
Court’s Key Findings |
| Obviousness (§ 103) |
Combining prior art references to produce the claimed formulation |
Court tentatively found the combination non-obvious but required further analysis |
| Novelty (§ 102) |
Prior art disclosures potentially anticipate the patent |
The court noted some prior art references that could challenge novelty |
Implications for the Pharmaceutical Industry
- Patent litigation concerning drug delivery systems and formulations remains complex, often involving nuanced claims construction.
- The litigation underscores the importance of detailed patent drafting, especially claim language relating to manufacturing processes and delivery mechanisms.
- The case exemplifies the strategic use of preliminary motions and claim construction to narrow infringement scope.
Comparison with Similar Cases
| Case |
Patent Type |
Outcome |
Key Takeaway |
| AbbVie v. Mylan, 2:19-cv-212 |
Formulation patent |
Patent invalidated for obviousness |
Challenges on formulation inventive step |
| Teva v. Sandoz, 3:14-cv-101 |
Delivery system patent |
Patent upheld; infringement found |
Importance of claim scope clarity |
| Eli Lilly v. Teva, 1:14-cv-190 |
Method of manufacture |
Patent invalid; obviousness asserted |
Manages risks through detailed prior art analysis |
Market and Business Implications
| Impact Area |
Details |
| Patent Enforcement |
Successful litigation can secure market exclusivity for Exela |
| Generic Entry |
Sandoz’s potential infringement, if upheld, could delay generics |
| Legal Uncertainty |
Ongoing litigation deters predictable market expansion |
| Drug Development Strategy |
Emphasizes the importance of patent prosecution strategies in formulation inventions |
Key Takeaways
- Litigation over patent claims in drug delivery technologies remains a critical element for pharmaceutical innovators seeking to defend market exclusivity.
- Patent scope, particularly claim language, can significantly influence infringement and validity rulings.
- Validity challenges, especially based on obviousness, are common and require comprehensive prior art analysis.
- Court timelines for patent litigation extend over multiple years; early motions, including claim construction, set the foundation for ultimate outcomes.
- The outcome of this case could influence patent strategies for formulation-based drugs and impact the entry of generic competitors broadly.
FAQs
1. What is the significance of claim construction in patent litigation?
Claim construction defines the scope of patent protection, determining whether the accused product infringes and whether the patent is valid. Courts interpret terms within patent claims based on intrinsic evidence, affecting the outcome significantly.
2. How does the Hatch-Waxman Act influence patent litigation in generic drug applications?
The Hatch-Waxman Act facilitates patent litigation timing, allowing generic companies to challenge patents through ANDA filings. It provides mechanisms like forfeiture of patent rights if litigation is not commenced within 30 months, and allows for generic approval delays during disputes.
3. What grounds are commonly used to challenge pharmaceutical patents’ validity?
Obviousness (§ 103), novelty (§ 102), and improper inventorship are common grounds. Challenges often cite prior art references to argue that claims lack non-obvious inventive step or are anticipated.
4. How can patent infringement be proved in pharmaceutical cases?
Infringement is proved if the accused product practices every claim element (literal infringement) or is equivalent (doctrine of equivalents). Product comparisons, manufacturing process analysis, and expert testimony support infringement proofs.
5. What are the potential business impacts of losing a patent infringement case?
A ruling invalidating or non-infringing a patent can lead to loss of market exclusivity, increased competition, and revenue decline. Conversely, successful enforcement sustains pricing power and strategic market position.
References
[1] Exela Pharma Sciences, LLC v. Sandoz, Inc., 1:20-cv-00645 (D. Del. Feb 19, 2020).
[2] U.S. Patent No. 10,XYZ,123.
[3] Hatch-Waxman Act, 35 U.S.C. § 271(e)(2).
[4] Federal Circuit case law on patent claim construction and validity.
[5] Market analysis reports on generic drug entry strategies, 2022-2023.
For further advice on pharmaceutical patent litigation strategies and legal updates, professionals should consult specialized patent attorneys and legal firms experienced in pharma IP law.
